On November 3, 2022 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported that the Company will present data relating to its highly selective CDK9 inhibitor, GFH009, during two poster presentations at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting being held on December 10-13, 2022 in New Orleans, Louisiana (Press release, Sellas Life Sciences, NOV 3, 2022, View Source [SID1234622938]). The meeting will also take place virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the first poster presentation, SELLAS will share data related to GFH009’s mechanism of action associated anti-proliferative activity in various hematologic malignancies. The second poster presentation highlights preliminary safety and efficacy data from the first-in-human study of GFH009 in patients with relapsed / refractory hematologic malignancies.